Terms: = Endocrine gland cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
845 results:
1. Efficacy and safety of pd-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
3. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
4. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
Nie H; Saini P; Miyamoto T; Liao L; Zielinski RJ; Liu H; Zhou W; Wang C; Murphy B; Towers M; Yang T; Qi Y; Kannan T; Kossenkov A; Tateno H; Claiborne DT; Zhang N; Abdel-Mohsen M; Zhang R
Nat Commun; 2024 Apr; 15(1):2853. PubMed ID: 38565883
[TBL] [Abstract] [Full Text] [Related]
5. Circulating tumor-associated antigen-specific IFNγ
Murakami H; Takahama S; Akita H; Kobayashi S; Masuta Y; Nagatsuka Y; Higashiguchi M; Tomokuni A; Yoshida K; Takahashi H; Doki Y; Eguchi H; Matsuura N; Yamamoto T
Front Immunol; 2024; 15():1363568. PubMed ID: 38550601
[TBL] [Abstract] [Full Text] [Related]
6. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova L; Rakova J; Hensler M; Lanickova T; Tomankova J; Pasulka J; Drozenova J; Mojzisova K; Fialova A; Vosahlikova S; Laco J; Ryska A; Dundr P; Kocian R; Brtnicky T; Skapa P; Capkova L; Kovar M; Prochazka J; Praznovec I; Koblizek V; Taskova A; Tanaka H; Lischke R; Mendez FC; Vachtenheim J; Heinzelmann-Schwarz V; Jacob F; McNeish IA; Halaska MJ; Rob L; Cibula D; Orsulic S; Galluzzi L; Spisek R; Fucikova J
Nat Commun; 2024 Mar; 15(1):2528. PubMed ID: 38514660
[TBL] [Abstract] [Full Text] [Related]
7. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
8. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract] [Full Text] [Related]
9. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
[TBL] [Abstract] [Full Text] [Related]
10. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Nakazawa Y; Miyano M; Tsukamoto S; Kogai H; Yamamoto A; Iso K; Inoue S; Yamane Y; Yabe Y; Umihara H; Taguchi J; Akagi T; Yamaguchi A; Koga M; Toshimitsu K; Hirayama T; Mukai Y; Machinaga A
Nat Commun; 2024 Mar; 15(1):2192. PubMed ID: 38467634
[TBL] [Abstract] [Full Text] [Related]
11. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
12. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
13. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
[TBL] [Abstract] [Full Text] [Related]
14. Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies.
Li X; Xiao C; Li R; Zhang P; Yang H; Cao D
Front Immunol; 2024; 15():1326556. PubMed ID: 38415262
[TBL] [Abstract] [Full Text] [Related]
15. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way.
Balar PC; Apostolopoulos V; Chavda VP
Eur J Pharmacol; 2024 Apr; 969():176451. PubMed ID: 38408598
[TBL] [Abstract] [Full Text] [Related]
16. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
17. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis.
Chen Y; Zhang F; Zhang B; Trojanowicz B; Hämmerle M; Kleeff J; Sunami Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1990. PubMed ID: 38389400
[TBL] [Abstract] [Full Text] [Related]
18. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic cancer.
Gorchs L; Fernández-Moro C; Asplund E; Oosthoek M; Solders M; Ghorbani P; Sparrelid E; Rangelova E; Löhr MJ; Kaipe H
Cancer Res Commun; 2024 Feb; 4(2):460-474. PubMed ID: 38335302
[TBL] [Abstract] [Full Text] [Related]
19. "RIPping" off Pancreas cancer's Blockage of Immune Surveillance.
Liu X; Sells BE; DeNardo DG
Cancer Discov; 2024 Feb; 14(2):208-210. PubMed ID: 38327192
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.
Wang J; Gai J; Zhang T; Niu N; Qi H; Thomas DL; Li K; Xia T; Rodriguez C; Parkinson R; Durham J; McPhaul T; Narang AK; Anders RA; Osipov A; Wang H; He J; Laheru DA; Herman JM; Lee V; Jaffee EM; Thompson ED; Zhu Q; Zheng L
Sci Adv; 2024 Feb; 10(6):eadk1827. PubMed ID: 38324679
[TBL] [Abstract] [Full Text] [Related]
[Next]
